Lycia Therapeutics, Inc. LYCA
Lycia Therapeutics, Inc. (Nasdaq: LYCA) is an immunology/inflammation drug developer. Its lead program, LCA-0061, is in Phase 1 for Food allergy and other allergic diseases. Its next catalyst on record is LCA-0062: Phase 1 clinical trial initiation and initial data (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LCA-0062 — Phase 1 clinical trial initiation and initial data (H2 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LCA-0061 | Food allergy and other allergic diseases (elevated IgE) | antibody | Phase 1 |
| LCA-0321 | Graves' disease (thyroid-stimulating hormone receptor autoantibodies) | protein/peptide | Phase 1 |
| LCA-0062 | Food allergy and other allergic diseases (IgE-mediated) | antibody | Pre-clinical |
Recent results and decisions
- Oct 26, 2026n/a Lycia Therapeutics closed its initial public offering and began trading on The Nasdaq Global Select Market under the ticker symbol LYCA.
On October 26, 2026, Lycia Therapeutics, Inc. (the 'Company') filed its Amended and Restated Certificate of Incorporation (the 'Charter') with the Secretary of State of the State of Delaware and its Amended and Restated Bylaws (the 'Bylaws') became effective in connection with the closing of the ini
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.